A kidney stone, 8 millimeters (0.31 in) in diameter
|Classification and external resources|
|ICD-10||N20.0 – N20.9|
|ICD-9-CM||592.0, 592.1, 592.9|
|Patient UK||Kidney stone|
A kidney stone, also known as a renal calculus or nephrolith, is a solid piece of material which is formed in the kidneys from minerals in urine. Kidney stones typically leave the body in the urine stream, and a small stone may pass without causing symptoms. If stones grow to sufficient size (usually at least 3 millimeters (0.12 in)) they can cause blockage of the ureter. This leads to pain, most commonly beginning in the flank or lower back and often radiating to the groin. This pain is often known as renal colic and typically comes in waves lasting 20 to 60 minutes. Other associated symptoms include: nausea, vomiting, fever, blood in the urine, pus in the urine, and painful urination. Blockage of the ureter can cause decreased kidney function and dilation of the kidney.
Most stones form due to a combination of genetics and environmental factors. Risk factors include being overweight, certain foods, some medications, and not drinking enough fluids. The diagnosis is usually based on symptoms, urine testing, and medical imaging. Blood tests may also be useful. Urinary stones are typically classified by their location in the kidney (nephrolithiasis), ureter (ureterolithiasis), or bladder (cystolithiasis), or by their chemical composition (calcium-containing, struvite, uric acid, or other compounds).
In those who have previously had stones, prevention is recommended by drinking fluids such that more than two liters of urine is produced per day. If this is not effective enough, thiazide diuretic, citrate or allopurinol may be taken. It is recommended that soft drinks containing phosphoric acid (typically colas) be avoided. When a stone causes no symptoms, no treatment is needed. For stones which are causing symptoms, pain control is usually the first measure, using medications such as nonsteroidal anti-inflammatory drugs or opioids. More severe cases may require procedures. For example, some stones can be shattered into smaller fragments using extracorporeal shock wave lithotripsy. Others require cystoscopic procedures.
- 1 Signs and symptoms
- 2 Risk factors
- 3 Pathophysiology
- 4 Diagnosis
- 5 Prevention
- 6 Management
- 7 Epidemiology
- 8 History
- 9 Research directions
- 10 Children
- 11 See also
- 12 Footnotes
- 13 External links
Signs and symptoms
The hallmark of a stone that obstructs the ureter or renal pelvis is excruciating, intermittent pain that radiates from the flank to the groin or to the inner thigh. This pain, known as renal colic, is often described as one of the strongest pain sensations known. Renal colic caused by kidney stones is commonly accompanied by urinary urgency, restlessness, hematuria, sweating, nausea, and vomiting. It typically comes in waves lasting 20 to 60 minutes caused by peristaltic contractions of the ureter as it attempts to expel the stone. The embryological link between the urinary tract, the genital system, and the gastrointestinal tract is the basis of the radiation of pain to the gonads, as well as the nausea and vomiting that are also common in urolithiasis. Postrenal azotemia and hydronephrosis can be observed following the obstruction of urine flow through one or both ureters. Pain in the lower left quadrant can sometimes be confused with diverticulitis because the sigmoid colon overlaps the ureter and the exact location of the pain may be difficult to isolate due to the close proximity of these two structures.
High dietary intake of animal protein, sodium, refined sugars, fructose and high fructose corn syrup, oxalate, grapefruit juice, and apple juice may increase the risk of kidney stone formation.
Kidney stones can result from an underlying metabolic condition, such as distal renal tubular acidosis, Dent's disease, hyperparathyroidism, primary hyperoxaluria, or medullary sponge kidney. 3–20% of people who form kidney stones have medullary sponge kidney.
A person with recurrent kidney stones may be screened for such disorders. This is typically done with a 24-hour urine collection. The urine is analyzed for features that promote stone formation.
Calcium is one component of the most common type of human kidney stones, calcium oxalate. Some studies[which?] suggest people who take calcium as a dietary supplement have a higher risk of developing kidney stones. In the United States, those findings were used[by whom?] as the basis for setting the Reference Daily Intake for calcium in adults.
In the early 1990s, a study conducted for the Women's Health Initiative in the US found that postmenopausal women who consumed 1000 mg of supplemental calcium and 400 international units of vitamin D per day for seven years had a 17% higher risk of developing kidney stones than subjects taking a placebo. The Nurses' Health Study also showed an association between supplemental calcium intake and kidney stone formation.
Unlike supplemental calcium, high intakes of dietary calcium do not appear to cause kidney stones and may actually protect against their development. This is perhaps related to the role of calcium in binding ingested oxalate in the gastrointestinal tract. As the amount of calcium intake decreases, the amount of oxalate available for absorption into the bloodstream increases; this oxalate is then excreted in greater amounts into the urine by the kidneys. In the urine, oxalate is a very strong promoter of calcium oxalate precipitation—about 15 times stronger than calcium. A 2004 study found that diets low in calcium are associated with a higher overall risk for kidney stone formation. For most individuals, other risk factors for kidney stones, such as high intakes of dietary oxalates and low fluid intake, play a greater role than calcium intake.
Calcium is not the only electrolyte that influences the formation of kidney stones. For example, by increasing urinary calcium excretion, high dietary sodium may increase the risk of stone formation.
Drinking fluoridated tap water may increase the risk of kidney stone formation by a similar mechanism, though further epidemiologic studies are warranted to determine whether fluoride in drinking water is associated with an increased incidence of kidney stones. High dietary intake of potassium appears to reduce the risk of stone formation because potassium promotes the urinary excretion of citrate, an inhibitor of calcium crystal formation.
Kidney stones are more likely to develop, and to grow larger, if a person has low dietary magnesium. Magnesium inhibits stone formation.
Diets in Western nations typically contain a large proportion of animal protein. Consumption of animal protein creates an acid load that increases urinary excretion of calcium and uric acid and reduced citrate. Urinary excretion of excess sulfurous amino acids (e.g., cysteine and methionine), uric acid, and other acidic metabolites from animal protein acidifies the urine, which promotes the formation of kidney stones. Low urinary citrate excretion is also commonly found in those with a high dietary intake of animal protein, whereas vegetarians tend to have higher levels of citrate excretion. Low urinary citrate, too, promotes stone formation.
The evidence linking vitamin C supplements with an increased rate of kidney stones is inconclusive. The excess dietary intake of vitamin C might increase the risk of calcium oxalate stone formation, in practice this is rarely encountered. The link between vitamin D intake and kidney stones is also tenuous. Excessive vitamin D supplementation may increase the risk of stone formation by increasing the intestinal absorption of calcium; correction of a deficiency does not.
There are no conclusive data demonstrating a cause-and-effect relationship between alcoholic beverage consumption and kidney stones. However, some have theorized that certain behaviors associated with frequent and binge drinking can lead to dehydration, which can in turn lead to the development of kidney stones.
The American Urological Association has projected that global warming will lead to an increased incidence of kidney stones in the United States by expanding the "kidney stone belt" of the southern United States.
People with lymphoproliferative/myeloproliferative disorders who were treated with chemotherapy developed symptomatic kidney stones 1.8% of the time in one study.
Supersaturation of urine
When the urine becomes supersaturated (when the urine solvent contains more solutes than it can hold in solution) with one or more calculogenic (crystal-forming) substances, a seed crystal may form through the process of nucleation. Heterogeneous nucleation (where there is a solid surface present on which a crystal can grow) proceeds more rapidly than homogeneous nucleation (where a crystal must grow in liquid medium with no such surface), because it requires less energy. Adhering to cells on the surface of a renal papilla, a seed crystal can grow and aggregate into an organized mass. Depending on the chemical composition of the crystal, the stone-forming process may proceed more rapidly when the urine pH is unusually high or low.
Supersaturation of the urine with respect to a calculogenic compound is pH-dependent. For example, at a pH of 7.0, the solubility of uric acid in urine is 158 mg/100 ml. Reducing the pH to 5.0 decreases the solubility of uric acid to less than 8 mg/100 ml. The formation of uric acid stones requires a combination of hyperuricosuria (high urine uric acid levels) and low urine pH; hyperuricosuria alone is not associated with uric acid stone formation if the urine pH is alkaline. Supersaturation of the urine is a necessary, but not a sufficient, condition for the development of any urinary calculus. Supersaturation is likely the underlying cause of uric acid and cystine stones, but calcium-based stones (especially calcium oxalate stones) may have a more complex etiology.
Inhibitors of stone formation
Normal urine contains chelating agents, such as citrate, that inhibit the nucleation, growth, and aggregation of calcium-containing crystals. Other endogenous inhibitors include calgranulin (an S-100 calcium binding protein), Tamm–Horsfall protein, glycosaminoglycans, uropontin (a form of osteopontin), nephrocalcin (an acidic glycoprotein), prothrombin F1 peptide, and bikunin (uronic acid-rich protein). The biochemical mechanisms of action of these substances have not yet been thoroughly elucidated. However, when these substances fall below their normal proportions, stones can form from an aggregation of crystals.
Sufficient dietary intake of magnesium and citrate inhibits the formation of calcium oxalate and calcium phosphate stones; in addition, magnesium and citrate operate synergistically to inhibit kidney stones. Magnesium's efficacy in subduing stone formation and growth is dose-dependent.
Diagnosis of kidney stones is made on the basis of information obtained from the history, physical examination, urinalysis, and radiographic studies. Clinical diagnosis is usually made on the basis of the location and severity of the pain, which is typically colicky in nature (comes and goes in spasmodic waves). Pain in the back occurs when calculi produce an obstruction in the kidney. Physical examination may reveal fever and tenderness at the costovertebral angle on the affected side.
Otherwise a noncontrast helical CT scan with 5 millimeters (0.20 in) sections is the diagnostic modality of choice in the radiographic evaluation of suspected nephrolithiasis. All stones are detectable on CT scans except very rare stones composed of certain drug residues in the urine, such as from indinavir. Calcium-containing stones are relatively radiodense, and they can often be detected by a traditional radiograph of the abdomen that includes the kidneys, ureters, and bladder (KUB film). Some 60% of all renal stones are radiopaque. In general, calcium phosphate stones have the greatest density, followed by calcium oxalate and magnesium ammonium phosphate stones. Cystine calculi are only faintly radiodense, while uric acid stones are usually entirely radiolucent.
Where a CT scan is unavailable, an intravenous pyelogram may be performed to help confirm the diagnosis of urolithiasis. This involves intravenous injection of a contrast agent followed by a KUB film. Uroliths present in the kidneys, ureters or bladder may be better defined by the use of this contrast agent. Stones can also be detected by a retrograde pyelogram, where a similar contrast agent is injected directly into the distal ostium of the ureter (where the ureter terminates as it enters the bladder).
Ultrasound imaging of the kidneys can sometimes be useful, as it gives details about the presence of hydronephrosis, suggesting the stone is blocking the outflow of urine. Radiolucent stones, which do not appear on KUB, may show up on ultrasound imaging studies. Other advantages of renal ultrasonography include its low cost and absence of radiation exposure. Ultrasound imaging is useful for detecting stones in situations where X-rays or CT scans are discouraged, such as in children or pregnant women. Despite these advantages, renal ultrasonography in 2009 was not considered a substitute for noncontrast helical CT scan in the initial diagnostic evaluation of urolithiasis. The main reason for this is that compared with CT, renal ultrasonography more often fails to detect small stones (especially ureteral stones), as well as other serious disorders that could be causing the symptoms. A 2014 study confirmed that ultrasonography rather than CT as an initial diagnostic test results in less radiation exposure and did not find any significant complications.
- microscopic examination of the urine, which may show red blood cells, bacteria, leukocytes, urinary casts and crystals;
- urine culture to identify any infecting organisms present in the urinary tract and sensitivity to determine the susceptibility of these organisms to specific antibiotics;
- complete blood count, looking for neutrophilia (increased neutrophil granulocyte count) suggestive of bacterial infection, as seen in the setting of struvite stones;
- renal function tests to look for abnormally high blood calcium blood levels (hypercalcemia);
- 24 hour urine collection to measure total daily urinary volume, magnesium, sodium, uric acid, calcium, citrate, oxalate and phosphate;
- collection of stones (by urinating through a StoneScreen kidney stone collection cup or a simple tea strainer) is useful. Chemical analysis of collected stones can establish their composition, which in turn can help to guide future preventive and therapeutic management.
Kidney stones are typically classified by their location and chemical composition.
|Kidney Stone type||Population||Circumstances||Color||Sensitivity||Details|
|Calcium oxalate||80%||when urine is acidic (decreased pH)||Black/Dark brown||Radio-opaque||Some of the oxalate in urine is produced by the body. Calcium and oxalate in the diet play a part but are not the only factors that affect the formation of calcium oxalate stones. Dietary oxalate is an organic molecule found in many vegetables, fruits, and nuts. Calcium from bone may also play a role in kidney stone formation.|
|Calcium phosphate||5–10%||when urine is alkaline (high pH)||Dirty white||Radio-opaque||Tends to grow in alkaline urine especially when proteus are present.|
|Uric acid||5–10%||when urine is persistently acidic||Yellow/Reddish brown||Radiolucent||Diets rich in animal proteins and purines: substances found naturally in all food but especially in organ meats, fish, and shellfish.|
|Struvite||10–15%||infections in the kidney||Dirty white||Radio-opaque||Preventing struvite stones depends on staying infection-free. Diet has not been shown to affect struvite stone formation.|
|Cystine||1–2%||rare genetic disorder||Pink/Yellow||Radio-opaque||Cystine, an amino acid (one of the building blocks of protein), leaks through the kidneys and into the urine to form crystals.|
|Xanthine||Extremely rare||Brick red||Radio-opaque|
By far, the most common type of kidney stones worldwide contains calcium. For example, calcium-containing stones represent about 80% of all cases in the United States; these typically contain calcium oxalate either alone or in combination with calcium phosphate in the form of apatite or brushite. Factors that promote the precipitation of oxalate crystals in the urine, such as primary hyperoxaluria, are associated with the development of calcium oxalate stones. The formation of calcium phosphate stones is associated with conditions such as hyperparathyroidism and renal tubular acidosis.
Oxaluria is increased in patients with certain gastrointestinal disorders including inflammatory bowel disease such as Crohn disease or patients who have undergone resection of the small bowel or small bowel bypass procedures. Oxaluria is also increased in patients who consume increased amounts of oxalate (found in vegetables and nuts). Primary hyperoxaluria is a rare autosomal recessive condition which usually presents in childhood.
Calcium oxalate crystals in urine appear as 'envelopes' microscopically. They may also form 'dumbbells.'
About 10–15% of urinary calculi are composed of struvite (ammonium magnesium phosphate, NH4MgPO4·6H2O). Struvite stones (also known as "infection stones", urease or triple-phosphate stones), form most often in the presence of infection by urea-splitting bacteria. Using the enzyme urease, these organisms metabolize urea into ammonia and carbon dioxide. This alkalinizes the urine, resulting in favorable conditions for the formation of struvite stones. Proteus mirabilis, Proteus vulgaris, and Morganella morganii are the most common organisms isolated; less common organisms include Ureaplasma urealyticum, and some species of Providencia, Klebsiella, Serratia, and Enterobacter. These infection stones are commonly observed in people who have factors that predispose them to urinary tract infections, such as those with spinal cord injury and other forms of neurogenic bladder, ileal conduit urinary diversion, vesicoureteral reflux, and obstructive uropathies. They are also commonly seen in people with underlying metabolic disorders, such as idiopathic hypercalciuria, hyperparathyroidism, and gout. Infection stones can grow rapidly, forming large calyceal staghorn (antler-shaped) calculi requiring invasive surgery such as percutaneous nephrolithotomy for definitive treatment.
Struvite stones (triple phosphate/magnesium ammonium phosphate) have a 'coffin lid' morphology by microscopy.
Uric acid stones
About 5–10% of all stones are formed from uric acid. People with certain metabolic abnormalities, including obesity, may produce uric acid stones. They also may form in association with conditions that cause hyperuricosuria (an excessive amount of uric acid in the urine) with or without hyperuricemia (an excessive amount of uric acid in the serum). They may also form in association with disorders of acid/base metabolism where the urine is excessively acidic (low pH), resulting in precipitation of uric acid crystals. A diagnosis of uric acid urolithiasis is supported by the presence of a radiolucent stone in the face of persistent urine acidity, in conjunction with the finding of uric acid crystals in fresh urine samples.
As noted above (section on calcium oxalate stones), patients with inflammatory bowel disease (Crohn's disease, ulcerative colitis) tend to have hyperoxaluria and form oxalate stones. These patients also have a tendency to form urate stones. Urate stones are especially common after colon resection.
Uric acid stones appear as pleomorphic crystals, usually diamond-shaped. They may also look like squares or rods which are polarizable.
Patients with hyperuricosuria can be treated with allopurinol which will reduce urate formation. Urine alkalinization may also be helpful in this setting.
People with certain rare inborn errors of metabolism have a propensity to accumulate crystal-forming substances in their urine. For example, those with cystinuria, cystinosis, and Fanconi syndrome may form stones composed of cystine. Cystine stone formation can be treated with urine alkalinization and dietary protein restriction. People afflicted with xanthinuria often produce stones composed of xanthine. People afflicted with adenine phosphoribosyltransferase deficiency may produce 2,8-dihydroxyadenine stones, alkaptonurics produce homogentisic acid stones, and iminoglycinurics produce stones of glycine, proline and hydroxyproline. Urolithiasis has also been noted to occur in the setting of therapeutic drug use, with crystals of drug forming within the renal tract in some people currently being treated with agents such as indinavir, sulfadiazine and triamterene.
Urolithiasis refers to stones originating anywhere in the urinary system, including the kidneys and bladder. Nephrolithiasis (from the Ancient Greek: νεφρός nephros, "kidney"; and λίθoς, lithos, "stone") refers to the presence of such calculi in the kidneys. Calyceal calculi refers to aggregations in either the minor or major calyx, parts of the kidney that pass urine into the ureter (the tube connecting the kidneys to the urinary bladder). The condition is called ureterolithiasis when a calculus is located in the ureter. Stones may also form or pass into the bladder, a condition referred to as cystolithiasis.
Preventative measures depend on the type of stones. In those with calcium stones, drinking lots of fluids, thiazide diuretics and citrate are effective as is allopurinol in those with high uric acid levels in the blood or urine.
Specific therapy should be tailored to the type of stones involved. Diet can have a profound influence on the development of kidney stones. Preventive strategies include some combination of dietary modifications and medications with the goal of reducing the excretory load of calculogenic compounds on the kidneys. Current dietary recommendations to minimize the formation of kidney stones include:
- Increasing total fluid intake to more than two liters per day of urine output.
- Increasing citric acid intake; lemon/lime juice is the richest natural source.
- Moderate calcium intake
- Limiting sodium intake
- Avoidance of large doses of supplemental vitamin C
- Limiting animal protein intake to no more than two meals daily (an association between animal protein consumption and recurrence of kidney stones has been shown in men).
- Limiting consumption of cola soft drinks, which contain phosphoric acid, to less than one liter of soft drink per week.
- Magnesium has also been shown to inhibit crystal formation thus reducing the risk for forming kidney stones. When 24-hour kidney stone risk profiles are performed, magnesium levels are a key indicator as to the potential stability of the urinary environment.
Maintenance of dilute urine by means of vigorous fluid therapy is beneficial in all forms of nephrolithiasis, so increasing urine volume is a key principle for the prevention of kidney stones. Fluid intake should be sufficient to maintain a urine output of at least 2 litres (68 US fl oz) per day. A high fluid intake has been associated with a 40% reduction in recurrence risk. The quality of the evidence for this, however, is not very good.
Calcium binds with available oxalate in the gastrointestinal tract, thereby preventing its absorption into the bloodstream, and reducing oxalate absorption decreases kidney stone risk in susceptible people. Because of this, some nephrologists and urologists recommend chewing calcium tablets during meals containing oxalate foods. Calcium citrate supplements can be taken with meals if dietary calcium cannot be increased by other means. The preferred calcium supplement for people at risk of stone formation is calcium citrate because it helps to increase urinary citrate excretion.
Aside from vigorous oral hydration and consumption of more dietary calcium, other prevention strategies include avoidance of large doses of supplemental vitamin C and restriction of oxalate-rich foods such as leaf vegetables, rhubarb, soy products and chocolate. However, no randomized, controlled trial of oxalate restriction has yet been performed to test the hypothesis that oxalate restriction reduces the incidence of stone formation. Some evidence indicates magnesium intake decreases the risk of symptomatic nephrolithiasis.
The mainstay for medical management of uric acid stones is alkalinization (increasing the pH) of the urine. Uric acid stones are among the few types amenable to dissolution therapy, referred to as chemolysis. Chemolysis is usually achieved through the use of oral medications, although in some cases, intravenous agents or even instillation of certain irrigating agents directly onto the stone can be performed, using antegrade nephrostomy or retrograde ureteral catheters. Acetazolamide (Diamox) is a medication that alkalinizes the urine. In addition to acetazolamide or as an alternative, certain dietary supplements are available that produce a similar alkalinization of the urine. These include sodium bicarbonate, potassium citrate, magnesium citrate, and Bicitra (a combination of citric acid monohydrate and sodium citrate dihydrate). Aside from alkalinization of the urine, these supplements have the added advantage of increasing the urinary citrate level, which helps to reduce the aggregation of calcium oxalate stones.
Increasing the urine pH to around 6.5 provides optimal conditions for dissolution of uric acid stones. Increasing the urine pH to a value higher than 7.0 increases the risk of calcium phosphate stone formation. Testing the urine periodically with nitrazine paper can help to ensure the urine pH remains in this optimal range. Using this approach, stone dissolution rate can be expected to be around 10 mm (0.39 in) of stone radius per month.
One of the recognized medical therapies for prevention of stones is the thiazide and thiazide-like diuretics, such as chlorthalidone or indapamide. These drugs inhibit the formation of calcium-containing stones by reducing urinary calcium excretion. Sodium restriction is necessary for clinical effect of thiazides, as sodium excess promotes calcium excretion. Thiazides work best for renal leak hypercalciuria (high urine calcium levels), a condition in which high urinary calcium levels are caused by a primary kidney defect. Thiazides are useful for treating absorptive hypercalciuria, a condition in which high urinary calcium is a result of excess absorption from the gastrointestinal tract.
For people with hyperuricosuria and calcium stones, allopurinol is one of the few treatments that have been shown to reduce kidney stone recurrences. Allopurinol interferes with the production of uric acid in the liver. The drug is also used in people with gout or hyperuricemia (high serum uric acid levels). Dosage is adjusted to maintain a reduced urinary excretion of uric acid. Serum uric acid level at or below 6 mg/100 ml) is often a therapeutic goal. Hyperuricemia is not necessary for the formation of uric acid stones; hyperuricosuria can occur in the presence of normal or even low serum uric acid. Some practitioners advocate adding allopurinol only in people in whom hyperuricosuria and hyperuricemia persist, despite the use of a urine-alkalinizing agent such as sodium bicarbonate or potassium citrate.
Stone size influences the rate of spontaneous stone passage. For example, up to 98% of small stones (less than 5 mm (0.20 in) in diameter) may pass spontaneously through urination within four weeks of the onset of symptoms, but for larger stones (5 to 10 mm (0.20 to 0.39 in) in diameter), the rate of spontaneous passage decreases to less than 53%. Initial stone location also influences the likelihood of spontaneous stone passage. Rates increase from 48% for stones located in the proximal ureter to 79% for stones located at the vesicoureteric junction, regardless of stone size. Assuming no high-grade obstruction or associated infection is found in the urinary tract, and symptoms are relatively mild, various nonsurgical measures can be used to encourage the passage of a stone. Repeat stone formers benefit from more intense management, including proper fluid intake and use of certain medications. In addition, careful surveillance clearly is required to maximize the clinical course for people who are stone formers.
The use of medications to speed the spontaneous passage of ureteral calculi is referred to as medical expulsive therapy. Several agents, including alpha adrenergic blockers (such as tamsulosin) and calcium channel blockers (such as nifedipine), have been found to be effective. Alpha blockers appear to lead to both higher and faster stone clearance rates. A combination of tamsulosin and a corticosteroid may be better than tamsulosin alone. These treatments also appear to be a useful adjunct to lithotripsy.
Extracorporeal shock wave lithotripsy (ESWL) is a noninvasive technique for the removal of kidney stones. Most ESWL is carried out when the stone is present near the renal pelvis. ESWL involves the use of a lithotriptor machine to deliver externally applied, focused, high-intensity pulses of ultrasonic energy to cause fragmentation of a stone over a period of around 30–60 minutes. Following its introduction in the United States in February 1984, ESWL was rapidly and widely accepted as a treatment alternative for renal and ureteral stones. It is currently used in the treatment of uncomplicated stones located in the kidney and upper ureter, provided the aggregate stone burden (stone size and number) is less than 20 mm (0.79 in) and the anatomy of the involved kidney is normal. For a stone greater than 10 mm, ESWL may not help break the stone in one treatment; instead, two or three treatments may be needed. Some 80 to 85% of simple renal calculi can be effectively treated with ESWL. A number of factors can influence its efficacy, including chemical composition of the stone, presence of anomalous renal anatomy and the specific location of the stone within the kidney, presence of hydronephrosis, body mass index, and distance of the stone from the surface of the skin. Common adverse effects of ESWL include acute trauma, such as bruising at the site of shock administration, and damage to blood vessels of the kidney. In fact, the vast majority of people who are treated with a typical dose of shock waves using currently accepted treatment settings are likely to experience some degree of acute kidney injury. ESWL-induced acute kidney injury is dose-dependent (increases with the total number of shock waves administered and with the power setting of the lithotriptor) and can be severe, including internal bleeding and subcapsular hematomas. On rare occasions, such cases may require blood transfusion and even lead to acute renal failure. Hematoma rates may be related to the type of lithotriptor used; hematoma rates of less than 1% and up to 13% have been reported for different lithotriptor machines. Recent studies show reduced acute tissue injury when the treatment protocol includes a brief pause following the initiation of treatment, and both improved stone breakage and a reduction in injury when ESWL is carried out at slow shock wave rate.
In addition to the aforementioned potential for acute kidney injury, animal studies suggest these acute injuries may progress to scar formation, resulting in loss of functional renal volume. Recent prospective studies also indicate elderly people are at increased risk of developing new-onset hypertension following ESWL. In addition, a retrospective case-control study published by researchers from the Mayo Clinic in 2006 has found an increased risk of developing diabetes mellitus and hypertension in people who had undergone ESWL, compared with age and gender-matched people who had undergone nonsurgical treatment. Whether or not acute trauma progresses to long-term effects probably depends on multiple factors that include the shock wave dose (i.e., the number of shock waves delivered, rate of delivery, power setting, acoustic characteristics of the particular lithotriptor, and frequency of retreatment), as well as certain intrinsic predisposing pathophysiologic risk factors.
To address these concerns, the American Urological Association established the Shock Wave Lithotripsy Task Force to provide an expert opinion on the safety and risk-benefit ratio of ESWL. The task force published a white paper outlining their conclusions in 2009. They concluded the risk-benefit ratio remains favorable for many people. The advantages of ESWL include its noninvasive nature, the fact that it is technically easy to treat most upper urinary tract calculi, and that, at least acutely, it is a well-tolerated, low-morbidity treatment for the vast majority of people. However, they recommended slowing the shock wave firing rate from 120 pulses per minute to 60 pulses per minute to reduce the risk of renal injury and increase the degree of stone fragmentation.
Most stones under 5 mm (0.20 in) pass spontaneously. Prompt surgery may, nonetheless, be required with persons with only one working kidney, bilateral obstructing stones, a urinary tract infection and thus, it is presumed, an infected kidney, or intractable pain. Beginning in the mid-1980s, less invasive treatments such as extracorporeal shock wave lithotripsy, ureteroscopy, and percutaneous nephrolithotomy began to replace open surgery as the modalities of choice for the surgical management of urolithiasis. More recently, flexible ureteroscopy has been adapted to facilitate retrograde nephrostomy creation for percutaneous nephrolithotomy. This approach is still under investigation, though early results are favorable. Percutaneous nephrolithotomy or, rarely, anatrophic nephrolithotomy, is the treatment of choice for large or complicated stones (such as calyceal staghorn calculi) or stones that cannot be extracted using less invasive procedures.
Ureteroscopy has become increasingly popular as flexible and rigid fiberoptic ureteroscopes have become smaller. One ureteroscopic technique involves the placement of a ureteral stent (a small tube extending from the bladder, up the ureter and into the kidney) to provide immediate relief of an obstructed kidney. Stent placement can be useful for saving a kidney at risk for postrenal acute renal failure due to the increased hydrostatic pressure, swelling and infection (pyelonephritis and pyonephrosis) caused by an obstructing stone. Ureteral stents vary in length from 24 to 30 cm (9.4 to 11.8 in) and most have a shape commonly referred to as a "double-J" or "double pigtail", because of the curl at both ends. They are designed to allow urine to flow past an obstruction in the ureter. They may be retained in the ureter for days to weeks as infections resolve and as stones are dissolved or fragmented by ESWL or by some other treatment. The stents dilate the ureters, which can facilitate instrumentation, and they also provide a clear landmark to aid in the visualization of the ureters and any associated stones on radiographic examinations. The presence of indwelling ureteral stents may cause minimal to moderate discomfort, frequency or urgency incontinence, and infection, which in general resolves on removal. Most ureteral stents can be removed cystoscopically during an office visit under topical anesthesia after resolution of the urolithiasis.
More definitive ureteroscopic techniques for stone extraction (rather than simply bypassing the obstruction) include basket extraction and ultrasound ureterolithotripsy. Laser lithotripsy is another technique, which involves the use of a holmium:yttrium aluminium garnet (Ho:YAG) laser to fragment stones in the bladder, ureters, and kidneys.
Ureteroscopic techniques are generally more effective than ESWL for treating stones located in the lower ureter, with success rates of 93–100% using Ho:YAG laser lithotripsy. Although ESWL has been traditionally preferred by many practitioners for treating stones located in the upper ureter, more recent experience suggests ureteroscopic techniques offer distinct advantages in the treatment of upper ureteral stones. Specifically, the overall success rate is higher, fewer repeat interventions and postoperative visits are needed, and treatment costs are lower after ureteroscopic treatment when compared with ESWL. These advantages are especially apparent with stones greater than 10 mm (0.39 in) in diameter. However, because ureteroscopy of the upper ureter is much more challenging than ESWL, many urologists still prefer to use ESWL as a first-line treatment for stones of less than 10 mm, and ureteroscopy for those greater than 10 mm in diameter. Ureteroscopy is the preferred treatment in pregnant and morbidly obese people, as well as those with bleeding disorders.
|Country||Earliest prevalence (years)||Latest prevalence (years)|
|United States||2.6% (1964-1972)||5.2% (1988-1994)|
|Italy||1.2% (1983)||1.7% (1993-1994)|
|Scotland||3.8% (1977)||3.5% (1987)|
|Spain||0.1% (1977)||10.0% (1991)|
|Country||New cases per 100,000 (year)||Trend|
|United States||116 (2000)||decreasing|
Kidney stones affect all geographical, cultural, and racial groups. The lifetime risk is about 10 to 15% in the developed world, but can be as high as 20 to 25% in the Middle East. The increased risk of dehydration in hot climates, coupled with a diet 50% lower in calcium and 250% higher in oxalates compared to Western diets, accounts for the higher net risk in the Middle East. In the Middle East, uric acid stones are more common than calcium-containing stones. The number of deaths due to kidney stones is estimated at 19,000 per year being fairly consistent between 1990 and 2010.
In North America and Europe, the annual number of new cases per year of kidney stones is roughly 0.5%. In the United States, the prevalence (frequency in the population) of urolithiasis has increased from 3.2% to 5.2% from the mid-1970s to the mid-1990s. The total cost for treating urolithiasis was US$2 billion in 2003. About 65-80% of those with kidney stones are men; most stones in women are due to either metabolic defects (such as cystinuria) or infection. (p. 1057) Men most commonly experience their first episode between 30 and 40 years of age, whereas for women, the age at first presentation is somewhat later. The age of onset shows a bimodal distribution in women, with episodes peaking at 35 and 55 years. Recurrence rates are estimated at 50% over a 10-year and 75% over 20-year period, with some people experiencing ten or more episodes over the course of a lifetime.
A 2010 review concluded that rates of disease are increasing.
The existence of kidney stones was first recorded thousands of years ago, and lithotomy for the removal of stones is one of the earliest known surgical procedures. In 1901, a stone discovered in the pelvis of an ancient Egyptian mummy was dated to 4,800 BC. Medical texts from ancient Mesopotamia, India, China, Persia, Greece, and Rome all mentioned calculous disease. Part of the Hippocratic Oath suggests there were practicing surgeons in ancient Greece to whom physicians were to defer for lithotomies. The Roman medical treatise De Medicina by Aulus Cornelius Celsus contained a description of lithotomy, and this work served as the basis for this procedure until the 18th century.
Famous people who were kidney stone formers include Napoleon I, Epicurus, Napoleon III, Peter the Great, Louis XIV, George IV, Oliver Cromwell, Lyndon B. Johnson, Benjamin Franklin, Michel de Montaigne, Francis Bacon, Isaac Newton, Samuel Pepys, William Harvey, Herman Boerhaave, and Antonio Scarpa.
New techniques in lithotomy began to emerge starting in 1520, but the operation remained risky. After Henry Jacob Bigelow popularized the technique of litholapaxy in 1878, the mortality rate dropped from about 24% to 2.4%. However, other treatment techniques continued to produce a high level of mortality, especially among inexperienced urologists. In 1980, Dornier MedTech introduced extracorporeal shock wave lithotripsy for breaking up stones via acoustical pulses, and this technique has since come into widespread use.
Renal calculus is from the Latin rēnēs, "kidneys," and calculus, "pebble"). Lithiasis (stone formation) in the kidneys is called nephrolithiasis (//), from nephro- (kidney) + -lith (stone) + -iasis (disorder).
Crystallization of calcium oxalate appears to be inhibited by certain substances in the urine that retard the formation, growth, aggregation, and adherence of crystals to renal cells. By purifying urine using salt precipitation, isoelectric focusing, and size-exclusion chromatography, some researchers have found that calgranulin, a protein formed in the kidney, is a potent inhibitor of the in vivo formation of calcium oxalate crystals. Considering its extremely high levels of inhibition of growth and aggregation of calcium oxalate crystals, calgranulin might be an important intrinsic factor in the prevention of nephrolithiasis.
Although kidney stones do not often occur in children, the incidence is increasing. These stones are in the kidney in two thirds of reported cases, and in the ureter in the remaining cases. Older children are at greater risk independent of age and sex.
As with adults, most pediatric kidney stones are predominantly composed of calcium oxalate; struvite and calcium phosphate stones are less common. Calcium oxalate stones in children are associated with high amounts of calcium, oxalate, and magnesium in acidic urine.
- "Kidney Stones in Adults". February 2013. Retrieved 22 May 2015.
- Qaseem, A; Dallas, P; Forciea, MA; Starkey, M et al. (4 November 2014). "Dietary and pharmacologic management to prevent recurrent nephrolithiasis in adults: A clinical practice guideline from the American College of Physicians". Annals of Internal Medicine 161 (9): 659. doi:10.7326/M13-2908.
- Johri, N; Cooper, B; Robertson, W; Choong, S et al. (2010). "An update and practical guide to renal stone management". Nephron Clinical Practice 116 (3): c159–71. doi:10.1159/000317196. PMID 20606476.
- GBD 2013 Mortality and Causes of Death, Collaborators (17 December 2014). "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.". Lancet. doi:10.1016/S0140-6736(14)61682-2. PMID 25530442.
- Preminger, GM (2007). "Chapter 148: Stones in the Urinary Tract". In Cutler, RE. The Merck Manual of Medical Information Home Edition (3rd ed.). Whitehouse Station, New Jersey: Merck Sharp and Dohme Corporation.
- Nephrolithiasis~Overview at eMedicine § Background.
- Pearle, MS; Calhoun, EA; Curhan, GC (2007). "Ch. 8: Urolithiasis". In Litwin, MS; Saigal, CS. Urologic Diseases in America (NIH Publication No. 07–5512) (PDF). Bethesda, Maryland: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, United States Public Health Service, United States Department of Health and Human Services. pp. 283–319.
- Cavendish, M (2008). "Kidney disorders". Diseases and Disorders 2 (1st ed.). Tarrytown, New York: Marshall Cavendish Corporation. pp. 490–3. ISBN 978-0-7614-7772-3.
- Curhan, GC; Willett, WC; Rimm, EB; Spiegelman, D et al. (Feb 1996). "Prospective study of beverage use and the risk of kidney stones". American Journal of Epidemiology 143 (3): 240–7. doi:10.1093/oxfordjournals.aje.a008734. PMID 8561157.
- Knight, J; Assimos, DG; Easter, L; Holmes, RP (2010). "Metabolism of fructose to oxalate and glycolate". Hormone and Metabolic Research 42 (12): 868–73. doi:10.1055/s-0030-1265145. PMC 3139422. PMID 20842614.
- Moe, OW (2006). "Kidney stones: Pathophysiology and medical management" (PDF). The Lancet 367 (9507): 333–44. doi:10.1016/S0140-6736(06)68071-9. PMID 16443041.
- Thakker, RV (2000). "Pathogenesis of Dent's disease and related syndromes of X-linked nephrolithiasis" (PDF). Kidney International 57 (3): 787–93. doi:10.1046/j.1523-1755.2000.00916.x. PMID 10720930.
- National Endocrine and Metabolic Diseases Information Service (2006). "Hyperparathyroidism (NIH Publication No. 6–3425)". Information about Endocrine and Metabolic Diseases: A-Z list of Topics and Titles. Bethesda, Maryland: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Public Health Service, US Department of Health and Human Services. Retrieved 2011-07-27.
- Hoppe, B; Langman, CB (2003). "A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria". Pediatric Nephrology 18 (10): 986–91. doi:10.1007/s00467-003-1234-x. PMID 12920626.
- Reilly, RF, Jr, Ch. 13: "Nephrolithiasis". In Reilly Jr & Perazella 2005, pp. 192–207.
- National Kidney and Urologic Diseases Information Clearinghouse (2008). "Medullary Sponge Kidney (NIH Publication No. 08–6235)". Kidney & Urologic Diseases: A-Z list of Topics and Titles. Bethesda, Maryland: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Public Health Service, US Department of Health and Human Services. Retrieved 2011-07-27.
- National Digestive Diseases Information Clearinghouse (2006). "Crohn's Disease (NIH Publication No. 06–3410)". Digestive Diseases: A-Z List of Topics and Titles. Bethesda, Maryland: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, United States Public Health Service, United States Department of Health and Human Services. Retrieved 2011-07-27.
- Farmer, RG; Hossein Mir-Madjlessi, S; Kiser, WS (1974). "Urinary excretion of oxalate, calcium, magnesium, and uric acid in inflammatory bowel disease: Relationship to urolithiasis". Cleveland Clinic Quarterly 41 (3): 109–17. doi:10.3949/ccjm.41.3.109. PMID 4416806.
- "Summary". In Committee to Review Dietary Reference Intakes for Vitamin D and Calcium 2011, pp. 1–14.
- "Tolerable upper intake levels: Calcium and vitamin D". In Committee to Review Dietary Reference Intakes for Vitamin D and Calcium 2011, pp. 403–56.
- Parmar, MS (2004). "Kidney stones". British Medical Journal 328 (7453): 1420–4. doi:10.1136/bmj.328.7453.1420. PMC 421787. PMID 15191979.
- Liebman, M; Al-Wahsh, IA (2011). "Probiotics and Other Key Determinants of Dietary Oxalate Absorption" (PDF). Advances in Nutrition 2 (May): 254–60. doi:10.3945/an.111.000414. Retrieved 2011-07-27.
- Committee on Fluoride in Drinking Water of the National Academy of Sciences (2006). "Chapter 9: Effects on the Renal System". Fluoride in Drinking Water: A Scientific Review of EPA's Standards. Washington, DC: The National Academies Press. pp. 236–48. ISBN 0-309-65799-7.
- Riley, JM; Kim, H; Averch, TD; Kim, HJ (Oct 2013). "Effect of magnesium on calcium and oxalate ion binding". J Endourol 27 (12): 1487–92. doi:10.1089/end.2013.0173. PMID 24127630.
- Negri, AL; Spivacow, FR; Del Valle, EE (2013). "[Diet in the treatment of renal lithiasis. Pathophysiological basis]". Medicina (B Aires) 73 (3): 267–71. PMID 23732207.
- Goodwin, JS; Mangum, MR (1998). "Battling quackery: Attitudes about micronutrient supplements in American academic medicine". Archives of Internal Medicine 158 (20): 2187–91. doi:10.1001/archinte.158.20.2187. PMID 9818798.
- Rodman, JS; Seidman, C (1996). "Ch. 8: Dietary Troublemakers". In Rodman, JS; Seidman, C; Jones, R. No More Kidney Stones (1st ed.). New York: John Wiley & Sons, Inc. pp. 46–57. ISBN 978-0-471-12587-7.
- Brawer, MK; Makarov, DV; Partin, AW; Roehrborn, CG et al. (2008). "Best of the 2008 AUA Annual Meeting: Highlights from the 2008 Annual Meeting of the American Urological Association, May 17–22, 2008, Orlando, FL". Reviews in Urology 10 (2): 136–56. PMC 2483319. PMID 18660856.
- "What is the Incidence of Kidney Stones after Chemotherapy in Patients with Lymphoproliferative or Myeloproliferative Disorders?". Int Braz J Urol 40 (40): 772–80. Dec 2014. doi:10.1590/S1677-5538.IBJU.2014.06.08.
- Perazella, MA, Ch. 14: "Urinalysis". In Reilly Jr & Perazella 2005, pp. 209–26.
- Knudsen, BE; Beiko, DT; Denstedt, JD, Ch. 16: "Uric Acid Urolithiasis". In Stoller & Meng 2007, pp. 299–308.
- Nephrolithiasis~Overview at eMedicine § Pathophysiology.
- Coe, FL; Evan, A; Worcester, E (2005). "Kidney stone disease". The Journal of Clinical Investigation 115 (10): 2598–608. doi:10.1172/JCI26662. PMC 1236703. PMID 16200192.
- del Valle, EE; Spivacow, FR; Negri, AL (2013). "[Citrate and renal stones]". Medicina (B Aires) 73 (4): 363–8. PMID 23924538.
- Anoia, EJ; Paik, ML; Resnick, MI (2009). "Ch. 7: Anatrophic Nephrolithomy". In Graham, SD; Keane, TE. Glenn's Urologic Surgery (7th ed.). Philadelphia: Lippincott Williams & Wilkins. pp. 45–50. ISBN 978-0-7817-9141-0.
- Weaver, SH; Jenkins, P (2002). "Ch. 14: Renal and Urological Care". Illustrated Manual of Nursing Practice (3rd ed.). Lippincott Williams & Wilkins. ISBN 1-58255-082-4.
- American College of Emergency Physicians (October 27, 2014). "Ten Things Physicians and Patients Should Question". http://www.choosingwisely.org/. Retrieved 14 January 2015.
- Smith, RC; Varanelli, M (2000). "Diagnosis and management of acute ureterolithiasis: CT is truth". American Journal of Roentgenology 175 (1): 3–6. doi:10.2214/ajr.175.1.1750003. PMID 10882237.
- Fang, LST (2009). "Chapter 135: Approach to the Paient with Nephrolithiasis". In Goroll, AH; Mulley, AG. Primary care medicine: office evaluation and management of the adult patient (6th ed.). Philadelphia: Lippincott Williams & Wilkins. pp. 962–7. ISBN 978-0-7817-7513-7.
- Miller, NL; Lingeman, JE (2007). "Management of kidney stones" (PDF). BMJ 334 (7591): 468–72. doi:10.1136/bmj.39113.480185.80. PMC 1808123. PMID 17332586.
- Pietrow, PK; Karellas, ME (2006). "Medical management of common urinary calculi" (PDF). American Family Physician 74 (1): 86–94. PMID 16848382.
- Bushinsky, D; Coe, FL; Moe, OW (2007). "Ch. 37: Nephrolithiasis". In Brenner, BM. Brenner and Rector's The Kidney 1 (8th ed.). Philadelphia: WB Saunders. pp. 1299–349. ISBN 978-1-4160-3105-5.
- Smith, RC; Levine, JA; Rosenfeld, AT (1999). "Helical CT of urinary tract stones. Epidemiology, origin, pathophysiology, diagnosis, and management". Radiologic Clinics of North America 37 (5): 911–52, v. doi:10.1016/S0033-8389(05)70138-X. PMID 10494278.
- Cormier, CM; Canzoneri, BJ; Lewis, DF; Briery, C et al. (2006). "Urolithiasis in pregnancy: Current diagnosis, treatment, and pregnancy complications" (PDF). Obstetrical and Gynecological Survey 61 (11): 733–41. doi:10.1097/01.ogx.0000243773.05916.7a. PMID 17044950.
- Smith-Bindman, R; Aubin, C; Bailitz, J; Bengiamin, RN et al. (18 September 2014). "Ultrasonography versus computed tomography for suspected nephrolithiasis". The New England Journal of Medicine 371 (12): 1100–1110. doi:10.1056/NEJMoa1404446. PMID 25229916.
- National Kidney and Urologic Diseases Information Clearinghouse (2007). "Kidney Stones in Adults (NIH Publication No. 08–2495)". Kidney & Urologic Diseases: A-Z list of Topics and Titles. Bethesda, Maryland: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Public Health Service, US Department of Health and Human Services. Retrieved 2011-07-27.
- contributors, ed. Kenneth L. Becker... With 330 (2001). Principles and practice of endocrinology and metabolism (3 ed.). Philadelphia, Pa. [u.a.]: Lippincott, Williams & Wilkins. p. 684. ISBN 9780781717502.
- "Cystine stones". UpToDate. Retrieved 20 February 2014.
- Bailey & Love's/25th/1296
- National Endocrine and Metabolic Diseases Information Service (2008). "Renal Tubular Acidosis (NIH Publication No. 09–4696)". Kidney & Urologic Diseases: A-Z list of Topics and Titles. Bethesda, Maryland: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Public Health Service, US Department of Health and Human Services. Retrieved 2011-07-27.
- De Mais, Daniel (2009). ASCP Quick Compendium of Clinical Pathology (2nd ed.). Chicago: ASCP Press.
- Weiss, M; Liapis, H; Tomaszewski, JE; Arend, LJ (2007). "Chapter 22: Pyelonephritis and Other Infections, Reflux Nephropathy, Hydronephrosis, and Nephrolithiasis". In Jennette, JC; Olson, JL; Schwartz, MM; Silva, FG. Heptinstall's Pathology of the Kidney 2 (6th ed.). Philadelphia: Lippincott Williams & Wilkins. pp. 991–1082. ISBN 978-0-7817-4750-9.
- Halabe, A; Sperling, O (1994). "Uric acid nephrolithiasis". Mineral and Electrolyte Metabolism 20 (6): 424–31. ISSN 0378-0392. PMID 7783706.
- Kamatani, N (1996). "Adenine phosphoribosyltransferase (APRT) deficiency". Nippon Rinsho. Japanese Journal of Clinical Medicine (in Japanese) 54 (12): 3321–7. ISSN 0047-1852. PMID 8976113.
- Rosenberg, LE; Durant, JL; Elsas, LJ (1968). "Familial iminoglycinuria. An inborn error of renal tubular transport". The New England Journal of Medicine 278 (26): 1407–13. doi:10.1056/NEJM196806272782601. PMID 5652624.
- Coşkun, T; Ozalp, I; Tokatli, A (1993). "Iminoglycinuria: A benign type of inherited aminoaciduria". The Turkish Journal of Pediatrics 35 (2): 121–5. PMID 7504361.
- Merck Sharp & Dohme Corporation (2010). "Patient Information about Crixivan for HIV (Human Immunodeficiency Virus) Infection" (PDF). Crixivan® (indinavir sulfate) Capsules. Whitehouse Station, New Jersey: Merck Sharp & Dohme Corporation. Retrieved 2011-07-27.
- Schlossberg, D; Samuel, R (2011). "Sulfadiazine". Antibiotic Manual: A Guide to Commonly Used Antimicrobials (1st ed.). Shelton, Connecticut: People's Medical Publishing House. pp. 411–12. ISBN 978-1-60795-084-4.
- Carr, MC; Prien, EL, Jr; Babayan, RK (1990). "Triamterene nephrolithiasis: Renewed attention is warranted". The Journal of Urology 144 (6): 1339–40. PMID 2231920.
- McNutt, WF (1893). "Chapter VII: Vesical Calculi (Cysto-lithiasis)". Diseases of the Kidneys and Bladder: A Text-book for Students of Medicine. IV: Diseases of the Bladder. Philadelphia: J.B. Lippincott Company. pp. 185–6.
- Fink, HA; Wilt, TJ; Eidman, KE; Garimella, PS et al. (2 April 2013). "Medical management to prevent recurrent nephrolithiasis in adults: A systematic review for an American College of Physicians clinical guideline". Annals of Internal Medicine 158 (7): 535–43. doi:10.7326/0003-4819-158-7-201304020-00005. PMID 23546565.
- Qaseem, A; Dallas, P; Forciea, MA; Starkey, M; Denberg, TD; Clinical Guidelines Committee of the American College of, Physicians (4 November 2014). "Dietary and pharmacologic management to prevent recurrent nephrolithiasis in adults: a clinical practice guideline from the American College of Physicians.". Annals of internal medicine 161 (9): 659–67. doi:10.7326/m13-2908. PMID 25364887.
- Goldfarb, DS; Coe, FL (1999). "Prevention of recurrent nephrolithiasis". American Family Physician 60 (8): 2269–76. PMID 10593318.
- Finkielstein, VA; Goldfarb, DS (2006). "Strategies for preventing calcium oxalate stones". Canadian Medical Association Journal 174 (10): 1407–9. doi:10.1503/cmaj.051517. PMC 1455427. PMID 16682705.
- Paterson, R; Fernandez, A; Razvi, H; Sutton, R (2010). "Evaluation and medical management of the kidney stone patient". Canadian Urological Association Journal 4 (6): 375–9. doi:10.5489/cuaj.10166. PMC 2997825. PMID 21191493.
- Penniston, Kristina, PhD, RD. Citric Acid and Kidney Stones. UW Hospital Metabolic Stone Clinic. Retrieved: 8 March 2015.
- Taylor, EN; Curhan, GC (September 2006). "Diet and fluid prescription in stone disease". Kidney international 70 (5): 835–9. doi:10.1038/sj.ki.5001656. PMID 16837923.
- "What are kidney stones?". kidney.org. Retrieved August 19, 2013.
- Heaney, RP (2006). "Nutrition and Chronic Disease" (PDF). Mayo Clinic Proceedings 81 (3): 297–9. doi:10.4065/81.3.297. PMID 16529131. Retrieved 2011-07-27.
- Tiselius, HG (2003). "Epidemiology and medical management of stone disease". British Journal of Urology International 91 (8): 758–67. doi:10.1046/j.1464-410X.2003.04208.x. PMID 12709088.
- Taylor, EN; Stampfer, MJ; Curhan, GC (2004). "Dietary factors and the risk of incident kidney stones in men: New insights after 14 years of follow-up" (PDF). Journal of the American Society of Nephrology 15 (12): 3225–32. doi:10.1097/01.ASN.0000146012.44570.20. PMID 15579526.
- Cicerello, E; Merlo, F; Maccatrozzo, L (Sep 2010). "Urinary alkalization for the treatment of uric acid nephrolithiasis". Archivio Italiano di Urologia, Andrologia 82 (3): 145–8. PMID 21121431.
- Cameron, JS; Simmonds, HA (1987). "Use and abuse of allopurinol". British Medical Journal 294 (6586): 1504–5. doi:10.1136/bmj.294.6586.1504. PMC 1246665. PMID 3607420.
- Gettman, MT; Segura, JW (2005). "Management of ureteric stones: Issues and controversies". British Journal of Urology International 95 (Supplement 2): 85–93. doi:10.1111/j.1464-410X.2005.05206.x. PMID 15720341.
- Macaluso, JN (1999). "Management of stone disease—bearing the burden". The Journal of Urology 156 (5): 1579–80. doi:10.1016/S0022-5347(01)65452-1. PMID 8863542.
- Seitz, C; Liatsikos, E; Porpiglia, F; Tiselius, HG et al. (September 2009). "Medical therapy to facilitate the passage of stones: What is the evidence?". European Urology 56 (3): 455–71. doi:10.1016/j.eururo.2009.06.012. PMID 19560860.
- Campschroer, T; Zhu, Y; Duijvesz, D; Grobbee, DE et al. (2 April 2014). "Alpha-blockers as medical expulsive therapy for ureteral stones". The Cochrane Database of Systematic Reviews 4: CD008509. doi:10.1002/14651858.CD008509.pub2. PMID 24691989.
- Campschroer, T; Zhu, Y; Duijvesz, D; Grobbee, DE; Lock, MT (2 April 2014). "Alpha-blockers as medical expulsive therapy for ureteral stones.". The Cochrane database of systematic reviews 4: CD008509. doi:10.1002/14651858.CD008509.pub2. PMID 24691989.
- Shock Wave Lithotripsy Task Force (2009). "Current Perspective on Adverse Effects in Shock Wave Lithotripsy" (PDF). Clinical Guidelines. Linthicum, Maryland: American Urological Association. Retrieved 2011-07-27.
- Lingeman, JE; Matlaga, BR; Evan, AP (2007). "Surgical Management of Urinary Lithiasis". In Wein, AJ; Kavoussi, LR; Novick, AC; Partin, AW; Peters, CA. Campbell-Walsh Urology. Philadelphia: W. B. Saunders. pp. 1431–1507.
- Preminger, GM; Tiselius, HG; Assimos, DG; Alken, P et al. (2007). "2007 Guideline for the management of ureteral calculi" (PDF). The Journal of Urology 178 (6): 2418–34. doi:10.1016/j.eururo.2007.09.039. PMID 17993340.
- Evan, AP; McAteer, JA (1996). "Ch. 28: Q-effects of Shock Wave Lithotripsy". In last1= Coe, FL; Favus, MJ; Pak, CYC; Parks, JH; Preminger, GM. Kidney Stones: Medical and Surgical Management. Philadelphia: Lippincott-Raven. pp. 549–60.
- Evan, AP; Willis, LR (2007). "Ch. 41: Extracorporeal Shock Wave Lithotripsy: Complications". In Smith, AD; Badlani, GH; Bagley, DH; Clayman, RV; Docimo, SG. Smith's Textbook on Endourology. Hamilton, Ontario, Canada: B C Decker, Inc. pp. 353–65.
- Young, JG; Keeley, FX, Ch. 38: "Indications for Surgical Removal, Including Asymptomatic Stones". In Rao, Preminger & Kavanagh 2011, pp. 441–54.
- Wynberg J et al. (Oct 2012). J Endourol 26 (10): 1268–74. Missing or empty
- Lam, JS; Gupta, M, Ch. 25: "Ureteral Stents". In Stoller & Meng 2007, pp. 465–83.
- Marks, AJ; Qiu, J; Milner, TE; Chan, KF et al., Ch. 26: "Laser Lithotripsy Physics". In Rao, Preminger & Kavanagh 2011, pp. 301–10.
- Romano, Victoriano; Akpinar, Haluk; Assimos, Dean G (2010). "Kidney Stones: A Global Picture of Prevalence, Incidence, and Associated Risk Factors". Rev. Urol. 12 (2010 Spring-Summer): 2–3. PMC 2931286. PMID 20811557.
- Lieske, JC; Segura, JW (2004). "Ch. 7: Evaluation and Medical Management of Kidney Stones". In Potts, JM. Essential Urology: A Guide to Clinical Practice (1st ed.). Totowa, New Jersey: Humana Press. pp. 117–52. ISBN 978-1-58829-109-7.
- Lozano, R; Naghavi, Mohsen; Foreman, Kyle; Lim, Stephen et al. (December 15, 2012). "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010". Lancet 380 (9859): 2095–128. doi:10.1016/S0140-6736(12)61728-0. PMID 23245604.
- Windus, editor, David (2008). The Washington manual nephrology subspecialty consult (2nd ed.). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins Health. p. 235. ISBN 9780781791496.
- Eknoyan, G (2004). "History of urolithiasis". Clinical Reviews in Bone and Mineral Metabolism 2 (3): 177–85. doi:10.1385/BMM:2:3:177. ISSN 1534-8644.
- Aulus Cornelius Celsus (1831). "Book VII, Chapter XXVI: Of the operation necessary in a suppression of urine, and lithotomy". In Collier, GF. A translation of the eight books of Aul. Corn. Celsus on medicine (2nd ed.). London: Simpkin and Marshall. pp. 306–14.
- Shah, J; Whitfield, HN (2002). "Urolithiasis through the ages". British Journal of Urology International 89 (8): 801–10. doi:10.1046/j.1464-410X.2002.02769.x. PMID 11972501.
- Ellis, H (1969). A History of Bladder Stone. Oxford, England: Blackwell Scientific Publications. ISBN 978-0-632-06140-2.
- Bigelow, HJ (1878). Litholapaxy or rapid lithotrity with evacuation. Boston: A. Williams and Company. p. 29.
- Coe, FL; Evan, A; Worcester, E (2008). "Chapter 114: Kidney stone disease". In Marks, AR; Neill, US. Science in medicine: the JCI textbook of molecular medicine. Part II: Kidney and urinary tract (1st ed.). Sudbury, Massachusetts: Jones and Bartlett Publishers. pp. 898–908. ISBN 978-0-7637-5083-1.
- Dwyer, Moira E.; Krambeck, Amy E.; Bergstralh, Eric J.; Milliner, Dawn S.; Lieske, John C.; Rule, Andrew D. (July 2012). "Temporal Trends in Incidence of Kidney Stones Among Children: A 25-Year Population Based Study". Pediatric Urology 188 (1): 247–252. doi:10.1016/j.juro.2012.03.021. PMID 22595060.
- "Diet and Definition of Kidney Stones, Renal Calculi". Retrieved 2013-10-11.
- Kirejczyk, JK.; Porowski, T.; Filonowicz, R.; Kazberuk, A.; Stefanowicz, M.; Wasilewska, A.; Debek, W. (Aug 2013). "An association between kidney stone composition and urinary metabolic disturbances in children". J Pediatr Urol 10 (1): 130–5. doi:10.1016/j.jpurol.2013.07.010. PMID 23953243.
- Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, Institute of Medicine of the National Academies (2011). Ross, AC; Taylor, CL; Yaktine, AL; Del, HB, eds. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: The National Academies Press. ISBN 978-0-309-16394-1.
- Rao, PN; Preminger, GM; Kavanagh, JP, eds. (2011). Urinary Tract Stone Disease (1st ed.). London: Springer-Verlag. doi:10.1007/978-1-84800-362-0_26. ISBN 978-1-84800-361-3.
- Reilly Jr., RF; Perazella, MA, eds. (2005). Nephrology in 30 Days (1st ed.). New York: The McGraw-Hill Companies, Inc. ISBN 0-07-143701-0.
- Stoller, ML; Meng, MV, eds. (2007). Urinary stone disease: the practical guide to medical and surgical management (1st ed.). Totowa, New Jersey: Humana Press. ISBN 978-1-59259-972-1.
|Wikimedia Commons has media related to Kidney stones.|